Stem Cell Clinic

Transfusion-dependent Anemia Treatment Market Size, Status and Growth Opportunities by 2025 – The Market Plan

Treating the patients with transfusion-dependent anemia is complicated. The diagnosis of transfusion-dependent anemia is often difficult as numerous disorders might lead to transfusion-dependent anemia that includes bone marrow failure syndromes, inherited hemolytic anemias or congenital dyserythropoietic anemias. Though severe anemia leads to symptoms of reduced quality of life and fatigue, transfusion-dependent anemia upsurges the risk of organ complications caused by iron overload. It may also leads to an increased risk of the leukemia transformation. While recommending the primary therapy for treatment of transfusion-dependent anemia, the four response determinants that should be considered includes: age, endogenous erythropoietin production, karyotype and RBC transfusion burden along with duration. Majority of patients develop the transfusion-dependent anemia over their course of the disease. However, adverse effect on the natural course of transfusion-dependent anemia has merely recently appreciated. As per a study conducted by World Health Organization, about 15% of the anemic cancer patients are treated via RBC transfusions. Unfortunately, treatment of chronic anemia with recurrent transfusions is done followed with associated hazards.

The increasing FDA approval for drugs that effectively treats transfusion-dependent anemia across the globe is expected to drive revenue growth in the transfusion-dependent anemia treatment over the forecast years. The higher incidence of anemia along with other infections in transfusion-dependent patients is further expected to drive the need for transfusion-dependent anemia treatment therapies. The growing commercialization of transfusion-dependent anemia treatment therapies such as allogeneic stem cell therapy would cater revenue opportunities in global transfusion-dependent anemia treatment market. However, increase in mortality rate for the patients suffering with transfusion-dependent anemia owing to high costs of the treatment therapies is anticipated to restrain the growth of transfusion-dependent anemia treatment market.

Get Sample Copy of this report at https://www.persistencemarketresearch.com/samples/28840?source=atm

The global transfusion-dependent anemia treatment market is segmented on basis of treatment type, distribution channel and geographic region:

Segmentation by Treatment Type Therapeutic Drugs Erythroid-Stimulating Agents (ESAs) Immunomodulatory Drugs Hypomethylating Drugs Others Allogeneic Stem Cell Therapy Gene Therapy

Segmentation by Distribution Channel Institutional Sales Hospitals Ambulatory Surgical Centers (ASCs) Specialty Clinics Retail Sales Hospital Pharmacies Retail Pharmacies Online Pharmacies Drug Stores

Request Report Methodology at https://www.persistencemarketresearch.com/methodology/28840?source=atm

The transfusion-dependent anemia treatment market is categorized based on treatment type, distribution channel and region. Based on treatment type, the transfusion-dependent anemia treatment is classified into three major treatment types including therapeutic drugs, gene therapy and allogeneic stem cell therapy. Among the transfusion-dependent anemia treatment drugs, immunomodulatory drugs are the most preferred transfusion-dependent anemia treatment drug type. This drug type segment is expected to expand at a substantial CAGR over the forecast years. Hospital pharmacies and retail pharmacies followed by hospitals is projected to register substantial revenue growth over the forecast period.

On the basis of geography, North America transfusion-dependent anemia treatment market will show highest market growth and is expected to dominate the global transfusion-dependent anemia treatment market in the forecast period owing to the growing prevalence of transfusion-dependent anemia in the region. Also, increasing health care spending coupled with availability of skilled healthcare professionals and availability of better treatments options is anticipated to boost the transfusion-dependent anemia treatment growth in this region. The transfusion-dependent anemia treatment market in South Asia and East Asia countries is expected to show a significant CAGR growth in the transfusion-dependent anemia treatment market owing larger patients pool. However, the market for transfusion-dependent anemia treatment in Latin America and the Middle East and Africa regions are estimated to register slow growth over the forecast period.

Some of the major key manufacturers involved in global Transfusion-dependent Anemia Treatment market are bluebird bio, Inc., Novartis AG, Takeda Pharmaceuticals, Acceleron Pharma, Inc., Celgene Corporation and others.

The report covers exhaustive analysis on: Transfusion-dependent Anemia Treatment Market Segments Transfusion-dependent Anemia Treatment Market Dynamics Historical Actual Market Size, 2014 2018 Transfusion-dependent Anemia Treatment Market Size & Forecast 2019 to 2029 Transfusion-dependent Anemia Treatment Market Current Trends/Issues/Challenges Competition & Companies involved Transfusion-dependent Anemia Treatment Market Drivers and Restraints

Regional analysis includes North America Latin America Europe East Asia South Asia Oceania The Middle East & Africa

Report Highlights: Shifting Industry dynamics In-depth market segmentation Historical, current and projected industry size Recent industry trends Key Competition landscape Strategies of key players and product offerings Potential and niche segments/regions exhibiting promising growth A neutral perspective towards market performance

Request to view TOC at https://www.persistencemarketresearch.com/toc/28840?source=atm

Read more:
Transfusion-dependent Anemia Treatment Market Size, Status and Growth Opportunities by 2025 - The Market Plan

Chemotherapy Drugs Market Strategies, Major Industry Participants, Marketing Channels and Forecast To2018 2028 – Commerce Gazette

Chemotherapy is the type of treatment medication mostly used to treat cancer. The aim of chemo is to stop or prevent the growth of cancer cells. Chemotherapy mostly affects the rapid growing cancerous cells. In chemotherapy, a chemical drug is used to stop the growth of cancer cells. There are different types of chemotherapy drugs. Some of the chemotherapy drugs widely used for adjuvant and neoadjuvant chemo are Adriamycin, Ellence, Taxol, Taxotere, Cytoxan, Paraplatin, Abraxane, Navelbine, Xeloda, Gemzar, Ixempra, Halaven. All these chemotherapy drugs work on different phases of cell cycle. In chemotherapy, drugs can be given as monotherapy or in combination therapy. Chemotherapy drugs have a lot of side effects. During chemotherapy drugs treatment, many healthy normal cells get affected. According to the American Cancer Society Cancer statistics report 2018, newly diagnosed cancer cases is estimated to be 1,735,350 and around 609,640 cancer deaths occur in the United States. Moreover, according to Cancer Research U.K., 17 million new cancer cases were estimated worldwide and 9.6 million cancer deaths were recorded in 2018 and are projected to increase at an incidence rate of 62% worldwide during the forecast period 2018-2040.

Get Sample Copy of this report at https://www.persistencemarketresearch.com/samples/27301?source=atm

Chemotherapy has both pros and cons. The global chemotherapy drugs have significant potential that will drive the market. After an early stage cancer surgery, most of the oncologist follow chemotherapy drugs treatment to prevent further multiplication of cancerous cells which as a result will boost the chemotherapy drugs market. Apart from this, chemotherapy drugs have multiple benefits such as it helps to shrink the tumor cells, it reduces the growth of cancerous cells thereby increasing the life span of a person which as a result will increase the growth of chemotherapy drugs market. Development of treatment-related side effects is one of the significant disadvantages which may restrain the growth of chemotherapy drugs. Chemotherapy treatment is a time-consuming and lengthy process. Henceforth the chemotherapy drugs market may face challenges in the coming years as a new alternative has been developed such as immunotherapy, gene therapy and also high treatment cost may adversely affect the chemotherapy drugs market. Immunotherapy has become the area of interest in the treatment of cancer as it enhances the immune system to fight against the cancerous cells and also patients have minimal side effects unlike conventional therapies like chemotherapy or radiation. All these alternatives may suppress the growth of overall chemotherapy drugs market.

The global chemotherapy drugs market is segmented on the basis of types, route of administration and distributional channel. Market Segmentation by types Alkylating Agents Antitumor Antibiotics Plant Alkaloids Antimetabolites Topoisomerase Inhibitors Miscellaneous Antineoplastic Market Segmentation by route of administration Intravenous Oral Intramuscular Subcutaneous Market Segmentation by end users Hospitals Ambulatory Surgical Centers Clinics Others

Request Report Methodology at https://www.persistencemarketresearch.com/methodology/27301?source=atm

North America and Europe collectively hold the largest share in the chemotherapy drugs market due to advanced healthcare facilities which provide effective treatment options and also increase launch of new cancer drugs and its approval from FDA and EMA which as a result will increase the chemotherapy drugs market. The Asia Pacific also have the potential to increase the global chemotherapy drugs market due to the rising prevalence of cancer in this region and increasing government initiatives for public health policies is likely to drive the global chemotherapy drugs market. The Middle East and Africa are shown to have less potential in chemotherapy drugs market due to low budget in healthcare spending, inappropriate treatment facilities which overall may impact the overall chemotherapy drugs treatment.

Some of the key players leading in chemotherapy drugs market are Novartis AG, Amgen Inc., F. Hoffmann-La Roche Ltd, Sanofi, Eli Lilly and Company, Almatica Pharma, Inc., Celgene Corporation, Johnson & Johnson Services, Inc., Pfizer Inc., AbbVie Inc., Merck & Co., Inc., Exelixis, Inc, Servier Pharmaceuticals LLC, AstraZeneca Pharmaceuticals LP, Celltrion Inc., Genentech, Inc., Astellas Pharma US Inc., Loxo Oncology Inc., Bayer HealthCare Pharmaceuticals Inc., Wyeth Pharmaceuticals Inc., Jazz Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Puma Biotechnology, Inc., EMD Serono, Inc. Takeda Pharmaceutical Company Limited, Tesaro, Inc., Clovis Oncology, Inc., and others.

The report covers exhaustive analysis on: Chemotherapy drugs Market Segments Chemotherapy drugs Market Dynamics Historical Actual Market Size, 2013 2017 Chemotherapy drugs Market Size & Forecast 2018 to 2028 Chemotherapy drugs Current Trends/Issues/Challenges Competition & Companies involved Chemotherapy drugs Market Drivers and Restraints

Regional analysis includes North America Latin America Europe Asia Pacific Middle East & Africa

Report Highlights: Shifting Industry dynamics In-depth market segmentation Historical, current and projected industry size Recent industry trends Key Competition landscape Strategies for key players and product offerings Potential and niche segments/regions exhibiting promising growth A neutral perspective towards market performance

Request to view TOC at https://www.persistencemarketresearch.com/toc/27301?source=atm

Continue reading here:
Chemotherapy Drugs Market Strategies, Major Industry Participants, Marketing Channels and Forecast To2018 2028 - Commerce Gazette

Targeted Cancer Therapies Market Regional Landscape, Production, Sales & Consumption Status and Prospects 2025 – Commerce Gazette

Targeted cancer therapies are drugs that are actively involved in blocking the growth of cancer by interfering with specific molecules which are responsible for the growth, progression, and spread of cancerous cells. These therapies are also known as precision medicines. Targeted cancer therapy is different from standard chemotherapy treatment as these therapies target only cancerous cells without affecting the normal cells. Also targeted cancer therapy block tumour cell proliferation, whereas standard chemotherapy kills the tumour cells. Recently targeted cancer therapies have gained increasing focus in anti-cancer drug development industry as these therapies forms the main branch of precision medicine i.e. a form of medicine that uses molecular diagnostic techniques to prevent, diagnose, and treat cancer. Targeted cancer therapies market comprises of the drugs used as precision medicine for treating malignant and benign tumours. Many drugs in targeted cancer therapies have been approved by FDA to treat various types of cancer and have been commercialized, whereas numerous cancer therapies are being studied in clinical trials and many are in preclinical testing.

Targeted cancer therapies market is growing, this is attributed to increasing prevalence of various types of cancers such as lung cancer, breast cancer, colorectal cancer, prostate cancer, lymphoma, leukaemia, melanoma etc. Also increasing awareness regarding molecular diagnostic techniques such as liquid biopsy to detect malignancy is expected to drive the market for targeted cancer therapies over the forecast period. Growing healthcare expenditure, and rising insurance coverage, aids in the revenue growth of targeted cancer therapies market. Increasing number of new targeted anti-cancerous drugs also drives the market for targeted anti-cancer drugs. However higher pricing of these drugs along with higher pricing of the molecular diagnostic tests to detect cancer is expected to hamper the growth of the targeted cancer therapies market over the forecast period.

The targeted cancer therapies market is segment based on the therapy type, end user and application

Targeted cancer therapies market is segmented into following types:

Get Sample Copy of this report at https://www.persistencemarketresearch.com/samples/13807?source=atm

By Therapy Type Hormone Therapies Signal Transduction Inhibitors Gene Expression Modulators Apoptosis Inducers Angiogenesis Inhibitors Immunotherapies Monoclonal Antibodies

By Disease Indication Gastrointestinal Lung Cancer Breast Cancer Colorectal Cancer Leukemia Lymphoma Melanoma Prostate Cancer Others

By End User Hospitals Cancer and Radiation Therapy Centers Clinics

Targeted cancer therapies market revenue is expected to grow at a significant rate, over the forecast period. The market is anticipated to perform well in the near future due to increasing awareness regarding various cancer types and their treatment protocols. Also the targeted cancer therapies market is expected to expand globally due increasing prevalence of cancer and increasing preference of oncologists to prescribe targeted anti-cancer drugs for the patients. The targeted therapies for lung cancer is anticipated to grow with a fastest CAGR over the forecast period, attributed to increasing number of smokers globally. Increasing competition among anti-cancer drug manufacturers, increasing investment in R&D and increasing number of new drug launches are the major factors estimated to drive the revenue growth of targeted cancer therapies market.

Depending on geographic region, the targeted cancer therapies market is segmented into five key regions: North America, Latin America, Europe, Asia Pacific (APAC) and Middle East & Africa (MEA).

Request Report Methodology at https://www.persistencemarketresearch.com/methodology/13807?source=atm

North America is occupying the largest regional market share in the global targeted cancer therapies market owing to the presence of more number of market players, high patient awareness levels, increasing healthcare expenditure and relatively larger number of R&D exercises pertaining to drug manufacturing and marketing activities in the region. Also Europe is expected to perform well in the near future due to increasing inclination of oncologists and physicians in the region prescribing targeted anti-cancerous drugs to the patients suffering from cancer.

Asia Pacific is expected to grow at the fastest CAGR because of increasing prevalence of different types of cancers in the region, thus boosting the market growth of targeted cancer therapies market throughout the forecast period.

Key players of targeted cancer therapies market includes Abbott Laboratories, Bayer HealthCare AG, GlaxoSmithKline plc, OncoGenex Pharmaceuticals Inc., Hospira Inc., Boehringer Ingelheim GmbH, AstraZeneca, Aveo Pharmaceuticals and many more. The companies in targeted cancer therapies market are increasingly engaged in strategic partnerships, collaborations, mergers and acquisitions to capture a greater pie of market share as the market is in the nascent stage.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to categories such as market segments, geographies, types, technology and applications.

The report covers exhaustive analysis on: Market Segments Market Dynamics Market Size Supply & Demand Current Trends/Issues/Challenges Competition & Companies involved Technology Value Chain

Regional analysis includes North America (U.S., Canada) Latin America (Argentina, Mexico, Brazil, Rest of Latin America) Europe (Germany, Italy, France, U.K., Spain, Russia, Rest of Europe) Asia Pacific (China, India, Japan, Rest of APAC) Middle East and Africa (Rest of MEA, S. Africa)

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Report Highlights: Detailed overview of parent market Changing market dynamics in the industry In-depth market segmentation Historical, current and projected market size in terms of volume and value Recent industry trends and developments Competitive landscape Strategies of key players and products offered Potential and niche segments, geographical regions exhibiting promising growth A neutral perspective on market performance Must-have information for market players to sustain and enhance their market footprint.

Request to view TOC at https://www.persistencemarketresearch.com/toc/13807?source=atm

Originally posted here:
Targeted Cancer Therapies Market Regional Landscape, Production, Sales & Consumption Status and Prospects 2025 - Commerce Gazette

Precision Cancer Therapies Market to Witness Comprehensive Growth by 2017 2025 – Technology Trend

Precision medicine (PM) can be defined as predictive, personalized, and preventive healthcare services delivery model. Precision cancer therapies is an additional option for patients suffering from cancer however it cannot completely replace the existing cancer treatments. Currently, researchers are making progress in the field of precision cancer therapies however many new and innovative drugs are currently in clinical trials. Precision cancer therapies include drugs or other substances which block the growth of cancer. Precision cancer therapies are also termed as molecular targeted therapy, or targeted molecular therapies, and precision medicines. Researchers are involved in developing anticancer drug developments via precision cancer therapies.

Precision Cancer Therapies Market: Segmentation

Get Sample Copy of this report at https://www.persistencemarketresearch.com/samples/17695?source=atm

Precision cancer therapies market can be segmented on the basis of the type of therapies, end users, and regions: Hormone Therapy Immunotherapies Targeted Therapy Monoclonal Antibody Therapy Gene Therapy

Precision cancer therapies market can be segmented on the basis of different end users in the market: Hospitals Diagnostic Centers Oncology Clinics Research Institutes

Precision Cancer Therapies Market: Dynamics

Request Report Methodology at https://www.persistencemarketresearch.com/methodology/17695?source=atm

Precision cancer therapies market is primarily driven by a few key factors such as the increasing prevalence of cancers, such as lung cancer, breast cancer, prostate cancer, melanoma and other types of cancers. The market is likely to grow owing to the increasing awareness regarding molecular diagnostic techniques which is expected to fuel the growth of precision cancer therapies market. The rising insurance coverage and growing healthcare expenditure by the government are among the factors which would aid the growth of precision cancer therapies market over the forecast years.

Precision cancer therapies market, however, faces various challenges such as the high cost of new and innovative therapies which prevent the wide prevention of these diseases. Precision cancer therapies market has various drugs which are still in various stages of clinical trials which refrain the products from the market. Precision cancer therapies market faces tremendous challenges due to the low awareness regarding the new diagnosis and treatment measures. Low-income countries and rising economies are coming forward to address such issues for precision cancer therapies market.

Precision Cancer Therapies Market: Region-wise Outlook

Based on geography, the precision cancer therapies market can be segmented into five major regions: North America, Europe, Asia-Pacific, Latin America and Middle East & Africa. At present, North America holds a leading position in the precision cancer therapies market due to the increasing incidence of cancer in the region which is followed by Europe. The major driving factors which have driven the growth of the precision cancer therapies market in this region is constant support of healthcare organizations in the development of new treatment methods, technological advancement in finding innovative treatment measures, and a rise in funding in public and private sector. Following North America, European countries are also anticipated to show steady growth in the precision cancer therapies market. Asia Pacific is expected to grow at the fastest CAGR because of increasing prevalence of different types of cancers in the region, thus boosting the market growth of precision cancer therapies market throughout the forecast period. The factors which would fuel the growth of precision cancer therapies market in Asia-Pacific are various multinational companies are setting up their operations in this region and aiming to gain huge revenue share from emerging countries, rising healthcare concerns, and improving healthcare scenario of the region. Precision cancer therapies market would evolve at a rapid rate across the regions. However, North America would maintain its position in the precision cancer therapies market, though, we are anticipating emerging economies such India, China, Brazil, Russia to have the highest growth in precision cancer therapies market.

Precision Cancer Therapies Market: Key Players

Precision cancer therapies market holds a huge number of players operating in the segment for years with expertise and experience. Various multinational companies are involved in the manufacturing of products which are utilized in the treatment of cancer. Such companies are Abbott Laboratories, Bayer HealthCare AG, GlaxoSmithKline plc, OncoGenex Pharmaceuticals Inc., Hospira Inc., Boehringer Ingelheim GmbH, AstraZeneca, Aveo Pharmaceuticals among others. Precision cancer therapies market has the presence of many regional players which have a huge market share in the emerging countries.

Request to view TOC at https://www.persistencemarketresearch.com/toc/17695?source=atm

View original post here:
Precision Cancer Therapies Market to Witness Comprehensive Growth by 2017 2025 - Technology Trend

Biological Product Manufacturing Market Analysis, Size, Regional Outlook, Share, Trend, Growth, Analysis and Forecast – Rapid News Network

Browse more detail information about this report visit at at https://www.transparencymarketresearch.com/biological-product-manufacturing-market.html

Biological products or biologics are therapeutic preparations that consist of natural complex biomolecules derived from living things. Active pharmaceutical ingredients (API), vaccines serum, and hematological products (whole blood and plasma derivatives), recombinant DNA products, cell cultures (micro-organisms or eukaryotic cells), gene therapy and cell therapy products, antigens, allergens, antivenoms, etc. are some examples of biological products. Due to the recent advances in supply chain management and favorable federal regulations, the biological products manufacturing industry has become a lucrative market for startups, contractual manufacturing companies, and strategic collaborations, equipped with skilled workers and affordable pricing. Increase in investments for R&D by various organizations, with an aim of manufacturing cost reduction and economical yet sustainable biological product manufacturing are serving as opportunities for many companies and collaborations in biological product manufacturing industries.

Request For Custom Research At https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=18758&source=atm

Major market players in the global biological product manufacturing market have various advantages such as cutting edge technologies, superior research and development, technologically advanced instruments, and skilled workforce to ensure proper assembly and delivery of the product. The biological product manufacturing market is driven by extensive R&D, along with increasing demand from health care providers across the world for advanced biological products, and growing focus by market players to provide quality products. However, competitive costs of therapeutic products, requirement of highly skilled labor for high value low volume biological product manufacturing, limited availability foreign capital, and stringent regulatory affairs regarding the manufacture of biological products are restraining the global biological product manufacturing market.

The global biological product manufacturing market has been segmented based on product type, end-user, application, and region. In terms of product type, the market is classified into bio-pharmaceutical products and biotechnological/biological products. The bio-pharmaceutical products segment includes vaccines, immunoglobulins, serum and other blood related product, allergens, antigens, antivenoms, and toxoids. The biotechnological/biological products segment includes micro-organism or eukaryotic cell culture, recombinant DNA technology products, gene therapy product, and cell therapy product. The biopharmaceuticals products segment accounted for the largest share of the global biological product manufacturing market. Based on end-user, the biological product manufacturing market has been segmented into hospitals, research and academic institutes, clinics and specialty trials, diagnostic labs, and others. The hospitals end-user segment accounted for the largest share of the global biological product manufacturing market, followed by research and academic institutes.

Superior technological advancements serve as a major opportunity in the biological product manufacturing market. Rising incidence of chronic diseases across the world, availability of better diagnostic facilities, advances in the drug discovery and pharmaceutical R&D sector, and rising government initiatives are some of the factors attributed to the high growth of the biological product manufacturing market. Increasing focus on discovery of heat labile or temperature sensitive products, advanced biopharmaceutical research in medicine, and invention of effective means to treat various diseases are expected to boost the growth of the biological product manufacturing market.

In terms of region, the global biological product manufacturing market has been segmented into five regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The market in Asia Pacific is projected to expand at a higher CAGR during the forecast period driven by factors such as low labor cost, less capital investment for manufacturing, increasing adoptions of new techniques in manufacturing of biological product, and favorable governmental policies. North America dominated the global biological product manufacturing market in 2015 due to factors such as new and technologically advanced products introduced in the market, significant investments in research and development of advanced products, and increasing patient demand for better health care facilities.

Key players in the biological product manufacturing market are Lonza, Advanced Life Sciences Holdings, Inc., Pfizer, Inc., Johnson & Johnson, Invitrogen, Amgen, Abbott Laboratories, Piramal Healthcare, and Shenhua Group Corp. Ltd. The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications. The study is a source of reliable data on: Market segments and sub-segments Market trends and dynamics Supply and demand Market size Current trends/opportunities/challenges Competitive landscape Technological breakthroughs Value chain and stakeholder analysis The regional analysis covers: North America (U.S. and Canada) Latin America (Mexico, Brazil, Peru, Chile, and others) Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg) Eastern Europe (Poland and Russia) Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand) Middle East and Africa (GCC, Southern Africa, and North Africa) The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industrys value chain. A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period. Highlights of the report: A complete backdrop analysis, which includes an assessment of the parent market Important changes in market dynamics Market segmentation up to the second or third level Historical, current, and projected size of the market from the standpoint of both value and volume Reporting and evaluation of recent industry developments Market shares and strategies of key players Emerging niche segments and regional markets An objective assessment of the trajectory of the market Recommendations to companies for strengthening their foothold in the market Note:Although care has been taken to maintain the highest levels of accuracy in TMRs reports, recent market/vendor-specific changes may take time to reflect in the analysis.

Request for TOC of This Report visit at https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=18758&source=atm

See original here:
Biological Product Manufacturing Market Analysis, Size, Regional Outlook, Share, Trend, Growth, Analysis and Forecast - Rapid News Network

Google Bans Advertising on Unproven Medical Treatments (like Stem Cells) – Bedford Bulletin

Closing out the first week of September, Google said it will no longer allow the posting of ads for unproven or experimental medical techniques.This includes, mostly, advertising that discusses or describes stem cell therapy, cellular therapy, and gene therapy.The Mountain View, CA-based technology giant said that this complex decision comes as a means to quell a rise in bad actors who try to take advantage of vulnerable people by offering untested, deceptive treatments.

In a recent blog post, Google said, These treatments can lead to dangerous health outcomes and we feel they have no place on our platforms, specifically ads for medical treatments with no established biomedical or scientific basis.

If this seems arbitrary to you then you may not have seen any of the onslaught of new ads from stem cell clinics across the United States looking to sell unapproved therapies which, they claim, can treat a wide range of ailments. This might include everything from arthritis to Alzheimers disease, from macular degeneration to multiple sclerosis.

And if you have not seen any of this type of advertising, you might want to be prepared to start.Stem cell clinics have been growing quickly as an emerging direct-to-consumer industry.And their growth may be largely due to the excitement generated by advertising the vast number of conditions that stem cells can supposedly treat.As a matter of fact, scientists and medical associations alike have commented that these unsupported claims make stem cell therapy like a modern snake oil that specifically aims to prey on seriously illand terribly vulnerablepatients.

While stem cell research has certainly had its breakthroughs, claiming that it can treat such a broad canvas of ailments is dangerous. Unfortunately, some stem cell treatments have already resulted in serious injury in some patients. Specifically, at least five women have reported going blind after a stem cell clinic injected their product directly into their eyes.

At the same time, some stem-cell industry representatives are criticizing Googles new ad policy. The argument is that this ban unfairly discriminates against good companies because there is no determination as to which companies actually provide a safe, FDA-verified procedure.Of course, Google should not have be a regulator in this industry, so the ban is more of an attempt to avoid any involvement with the potential risks.

See more here:
Google Bans Advertising on Unproven Medical Treatments (like Stem Cells) - Bedford Bulletin